The type I interleukin‐1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF‐transgenic mice
The DOI matches its Crossref record.
Abstract
The pro‐inflammatory cytokines tumor necrosis factor (TNF) and interleukin‐1 (IL‐1) have been shown to be primary mediators in the pathogenesis of chronic inflammatory joint diseases. However, the relative contributions of these molecules to the development and progression of disease is not known. In the present study, we have investigated the involvement of the type I IL‐1 receptor in the development and progression of chronic arthritis in a previously described TNF‐transgenic mouse model of this disease. A neutralizing monoclonal antibody to the murine type I IL‐1 receptor was injected intraperitoneally three times a week from birth to 9 weeks of age. In the positive control group of untreated transgenic mice the incidence of arthritis was 100% after 9 weeks of age. The injection of normal hamster IgG did not influence the incidence or development of arthritis. In contrast, the injection of antibody to the type I IL‐1 receptor completely prevented the development of arthritis. Clinical evaluation of disease was confirmed histologically, anti‐receptor antibody‐treated mice showed no sign of arthritic change. Moreover, the analysis of sera taken at the end of the study period showed that the neutralization of arthritis by IL‐1 receptor antibody treatment was accompanied by significantly lower levels of circulating human TNF compared to the control groups and to untreated transgenic mice prior to disease onset. Taken together, these results show that IL‐1 signaling blockade exerts a direct negative feedback effect on TNF production. Our results show that in TNF‐transgenic mice the IL‐1 receptor accepts the whole pathogenic load of TNF, thereby acting as a potent downstream mediator in the pathogenesis of chronic arthritis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
Feldmann, M., Brennan, F. M., & Maini, R. N. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.397 · Cited by 2,514
Interleukin 6 is required for the development of collagen-induced arthritis
Alonzi, T., Fattori, E., Lazzaro, D., Costa, P., Probert, L., Kollias, G., De Benedetti, F., Poli, V., & Ciliberto, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.4.461 · Cited by 604
“Moreover, it has been recently shown that most of the TNF-a activity in this model is mediated by its capacity to induce IL-1b and to synergize with it ( 45 ), and the constitutive expression of 39‐untranslated region‐modified TNF-a may not easily come under the control of regulatory factors, hence leading to an unbal…”
BackgroundSelf-citationAnti-TNF-α therapies: the next generation
Palladino, M. A., Bahjat, F. R., Theodorakis, E. A., & Moldawer, L. L. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1175 · Cited by 576
The roles of IL‐17A in inflammatory immune responses and host defense against pathogens
Iwakura, Y., Nakae, S., Saijo, S., & Ishigame, H. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00699.x · Cited by 513
(2008) · Arthritis & Rheumatism · doi:10.1002/art.23363 · Cited by 505
Charles, P., Elliott, M. J., Davis, D., Potter, A., Kalden, J. R., Antoni, C., Breedveld, F. C., Smolen, J. S., Eberl, G., deWoody, K., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1521 · Cited by 436
Probert, L., Akassoglou, K., Pasparakis, M., Kontogeorgos, G., & Kollias, G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.24.11294 · Cited by 403
Self-citationJoosten, L. A. B., Helsen, M. M. A., van de Loo, F. A. J., & van den Berg, W. B. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390513 · Cited by 400
Critical Roles for Interleukin 1 and Tumor Necrosis Factor α in Antibody-induced Arthritis
Ji, H., Pettit, A., Ohmura, K., Ortiz-Lopez, A., Duchatelle, V., Degott, C., Gravallese, E., Mathis, D., & Benoist, C. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020439 · Cited by 332
Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis?
Burmester, G. R., Stuhlmüller, B., Keyszer, G., & Kinne, R. W. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400104 · Cited by 318
Collagen-induced arthritis, an animal model of autoimmunity
Myers, L. K., Rosloniec, E. F., Cremer, M. A., & Kang, A. H. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00480-3 · Cited by 316
Hata, H., Sakaguchi, N., Yoshitomi, H., Iwakura, Y., Sekikawa, K., Azuma, Y., Kanai, C., Moriizumi, E., Nomura, T., Nakamura, T., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421795 · Cited by 304
TNF-induced structural joint damage is mediated by IL-1
Zwerina, J., Redlich, K., Polzer, K., Joosten, L., Krönke, G., Distler, J., Hess, A., Pundt, N., Pap, T., Hoffmann, O., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610812104 · Cited by 304
Kollias, G., Douni, E., Kassiotis, G., & Kontoyiannis, D. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01315.x · Cited by 263
Self-citationTreatment of arthritis with a selective inhibitor of c-Fos/activator protein-1
Aikawa, Y., Morimoto, K., Yamamoto, T., Chaki, H., Hashiramoto, A., Narita, H., Hirono, S., & Shiozawa, S. (2008) · Nature Biotechnology · doi:10.1038/nbt1412 · Cited by 214
Kollias, G., Douni, E., Kassiotis, G., & Kontoyiannis, D. (1999) · Annals of the Rheumatic Diseases · doi:10.1136/ard.58.2008.i32 · Cited by 210
“In addition, neutralisation of arthritis by treatment of the hTNF transgenic mice with antibodies against TNF or the type I IL1 receptor established the idea that a functional hierarchy exists, in which the IL1R acts in series and downstream of TNF to effect TNF mediated arthritogenic responses.”
BackgroundSelf-citationAstrocyte immune responses in epilepsy
Aronica, E., Ravizza, T., Zurolo, E., & Vezzani, A. (2012) · Glia · doi:10.1002/glia.22312 · Cited by 207
“Moreover, transgenic mice with low to moderate overexpression of TNF-a in astrocytes show decreased susceptibility to seizures (Balosso et al., 2005), whereas mice with high overexpression of TNF-a in astrocytes develop signs of neurologic dysfunction (Akassoglou et al., 1997; Probert et al., 1995).”
BackgroundTherapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation
DINARELLO, C. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.03.010 · Cited by 195
PATHOGENESIS OF RHEUMATOID ARTHRITIS
Panayi, G. S., Corrigall, V. M., & Pitzalis, C. (2001) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70204-0 · Cited by 189
Inhibition of IL-1, IL-6, and TNF-α in immune-mediated inflammatory diseases
Möller, B., & Villiger, P. M. (2006) · Springer Seminars in Immunopathology · doi:10.1007/s00281-006-0012-9 · Cited by 183
“The same was also true for antibody blockade of the IL-1RI, indicating that IL-1 is a potent downstream mediator of TNF-α in the pathogenesis of arthritis in these mice [33].”
Background
Metadata
- Authors
- Probert, L., Plows, D., Kontogeorgos, G., & Kollias, G.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 1995-06
- Volume
- 25
- Issue
- 6
- Pages
- 1794-1797
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W1968376159
- Cited by
- 155
- References
- 0
- FWCI
- 8.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.